Liquidia Co. (NASDAQ:LQDA) Receives $21.00 Consensus Price Target from Brokerages

Shares of Liquidia Co. (NASDAQ:LQDA) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $21.00.

LQDA has been the subject of several recent analyst reports. Oppenheimer initiated coverage on shares of Liquidia in a report on Tuesday. They issued a “market perform” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Liquidia in a report on Wednesday, May 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Liquidia in a report on Monday, June 3rd.

Insider Transactions at Liquidia

In other news, General Counsel Russell Schundler sold 2,060 shares of the stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $30,034.80. Following the completion of the sale, the general counsel now directly owns 486,027 shares of the company’s stock, valued at $7,086,273.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, General Counsel Russell Schundler sold 2,060 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $30,034.80. Following the transaction, the general counsel now owns 486,027 shares of the company’s stock, valued at $7,086,273.66. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Roger Jeffs sold 8,360 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $121,888.80. Following the transaction, the chief executive officer now directly owns 826,985 shares in the company, valued at approximately $12,057,441.30. The disclosure for this sale can be found here. Insiders sold 18,653 shares of company stock valued at $270,409 over the last three months. 31.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. Patient Square Capital LP bought a new position in Liquidia during the first quarter valued at approximately $105,942,000. Farallon Capital Management LLC acquired a new position in Liquidia during the first quarter valued at approximately $30,311,000. Vestal Point Capital LP acquired a new position in Liquidia during the fourth quarter valued at approximately $12,331,000. Kynam Capital Management LP grew its holdings in Liquidia by 34.9% during the fourth quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock valued at $32,461,000 after purchasing an additional 698,324 shares during the last quarter. Finally, Beryl Capital Management LLC acquired a new position in Liquidia during the third quarter valued at approximately $3,135,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Trading Up 0.5 %

NASDAQ:LQDA opened at $12.38 on Tuesday. Liquidia has a twelve month low of $5.71 and a twelve month high of $16.99. The company has a 50-day moving average of $12.87 and a 200-day moving average of $13.17. The firm has a market cap of $945.21 million, a price-to-earnings ratio of -7.94 and a beta of 0.25.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.22). Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. The business had revenue of $2.97 million for the quarter, compared to the consensus estimate of $4.31 million. On average, research analysts forecast that Liquidia will post -1.2 earnings per share for the current year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).